Progression and survival in Parkinson's disease with subthalamic nucleus stimulation.
Saved in:
| Title: | Progression and survival in Parkinson's disease with subthalamic nucleus stimulation. |
|---|---|
| Authors: | Lilleeng, B., Brønnick, K., Toft, M., Dietrichs, E., Larsen, J. P. |
| Source: | Acta Neurologica Scandinavica. Nov2014, Vol. 130 Issue 5, p292-298. 7p. |
| Subjects: | Parkinson's disease treatment, Disease progression, Neural stimulation, Subthalamic nucleus, Treatment effectiveness, Neuroprotective agents |
| Abstract: | Background Treatment for Parkinson's disease (PD) is symptomatic. Surgical treatment with continuous high-frequency stimulation of the subthalamic nucleus ( STN- DBS) is established as a safe symptomatic treatment with long-term beneficial effects. It has been postulated that STN- DBS could halt the progression of PD through a disease modifying or neuroprotective effect. Objective To investigate the postulated disease modifying or neuroprotective effect of STN- DBS by comparing the rate of deterioration of parkinsonism and mortality over time in two selected and matched groups of patients with PD with and without surgery. Methods Group A was derived from all patients who received STN- DSB surgery at Oslo University Hospital, from January 2001 to December 2007. Group B was derived from a prevalence study of PD in the Stavanger area of Western Norway in 1993. The two groups were individually matched and the disease progression measured by Unified Parkinson's Disease Rating Scale-motor scores, and the mortality was compared. Results The mean annual change based on baseline and last observation scores in individually matched groups was 0.97 ( SD = 3.57) for the surgery group and 1.04 ( SD = 3.33) for the controls and thus not significantly different, F(1, 104) = .21, P = 0.89. The long-term mortality was also similar in the two groups during long-term follow-up, hazard ratio = 1.76, CL 0.91-3.40, P = 0.091. Conclusion This study gives no support to a postulated disease modifying or neuroprotective effect of STN- DBS in patients with PD. [ABSTRACT FROM AUTHOR] |
| Copyright of Acta Neurologica Scandinavica is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | Psychology and Behavioral Sciences Collection |
|
Full text is not displayed to guests.
Login for full access.
|
|
| Abstract: | Background Treatment for Parkinson's disease (PD) is symptomatic. Surgical treatment with continuous high-frequency stimulation of the subthalamic nucleus ( STN- DBS) is established as a safe symptomatic treatment with long-term beneficial effects. It has been postulated that STN- DBS could halt the progression of PD through a disease modifying or neuroprotective effect. Objective To investigate the postulated disease modifying or neuroprotective effect of STN- DBS by comparing the rate of deterioration of parkinsonism and mortality over time in two selected and matched groups of patients with PD with and without surgery. Methods Group A was derived from all patients who received STN- DSB surgery at Oslo University Hospital, from January 2001 to December 2007. Group B was derived from a prevalence study of PD in the Stavanger area of Western Norway in 1993. The two groups were individually matched and the disease progression measured by Unified Parkinson's Disease Rating Scale-motor scores, and the mortality was compared. Results The mean annual change based on baseline and last observation scores in individually matched groups was 0.97 ( SD = 3.57) for the surgery group and 1.04 ( SD = 3.33) for the controls and thus not significantly different, F(1, 104) = .21, P = 0.89. The long-term mortality was also similar in the two groups during long-term follow-up, hazard ratio = 1.76, CL 0.91-3.40, P = 0.091. Conclusion This study gives no support to a postulated disease modifying or neuroprotective effect of STN- DBS in patients with PD. [ABSTRACT FROM AUTHOR] |
|---|---|
| ISSN: | 00016314 |
| DOI: | 10.1111/ane.12224 |
